ctDNA Dynamics and Recurrence Patterns after Organ-Sparing Trimodality Therapy for Bladder Cancer
ctDNA detectability is strongly correlated with metastatic but not local disease recurrence in patient with MIBC following TMT.
Authors
- Daniel A. Roberts
- David T. Miyamoto (ORCID: https://orcid.org/0000-0003-3692-8823)
- Ilana Epstein
- Isabella R. Pompa
- Timothy N. Clinton
- Charlene Mantia (ORCID: https://orcid.org/0000-0001-7672-3131)
- S. Berg
- Jason A. Efstathiou (ORCID: https://orcid.org/0000-0003-0996-0350)
- Arvind Ravi
- Jacob E. Berchuck (ORCID: https://orcid.org/0000-0002-7607-2428)
- Kent W. Mouw (ORCID: https://orcid.org/0000-0001-7939-7343)
- Yukako Otani (ORCID: https://orcid.org/0009-0006-4422-2782)
- Cameron Herberts
- Mark A. Preston (ORCID: https://orcid.org/0000-0003-1010-8464)
- Matthew Mossanen
- Adetolani Odogiyon
- Luke Peng
- Filipe Carvalho
- Sophia C. Kamran
- Joaquim Bellmunt
- Bradley McGregor
- Joshua Wan
- Anurag Saraf
- Adam ElNaggar
Institutions
- Brigham and Women's Hospital (US)
- Emory University (US)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
- Natera (United States) (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-26
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3712
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- Gilead Sciences
- Les Laboratories Pierre Fabre
- Astellas Pharma
- Ipsen
- Genentech
- EMD Serono